难治性急迫性尿失禁女性随机接受骶神经调节或膀胱内注射A型肉毒毒素与对照组的尿液生物标志物比较
本研究测量难治性急迫性尿失禁女性在基线及接受骶神经调节或膀胱内注射A型肉毒毒素(onabotulinumtoxinA)治疗6个月后的尿液生物标志物,并与年龄匹配的无急迫性尿失禁女性对照比较。基线时病例与对照仅原弹性蛋白(p=0.001)和I型胶原N端端肽(p<0.001)有差异。治疗6个月后两组胶原酶均下降(p<0.001),A型肉毒毒素组白细胞介素-8(p=0.002)和基质金属蛋白酶-9(p<0.001)升高。
要点
- 基线时病例与对照仅原弹性蛋白(p=0.001)和I型胶原N端端肽(p<0.001)有差异。
- 治疗6个月后两组胶原酶均下降(p<0.001),A型肉毒毒素组白细胞介素-8(p=0.002)和基质金属蛋白酶-9(p<0.001)升高。
- 基线降钙素基因相关肽较高与两种治疗后膀胱过度活动症症状困扰改善较少相关(p=0.007)。
核心结论
- 难治性急迫性尿失禁是复杂疾病,数据提示基质重塑和神经肽介导可能参与其病理生理机制及治疗反应。
研究设计与样本
- 对同意参与试验的难治性急迫性尿失禁女性及年龄匹配的无急迫性尿失禁女性采集晨尿,比较基线及治疗6个月后生物标志物水平。
- 治疗为骶神经调节或膀胱内注射A型肉毒毒素(onabotulinumtoxinA)。
- 使用标准化酶联免疫吸附试验和活性测定检测反映一般炎症、神经炎症、传入神经递质和组织重塑的生物标志物。
- 症状困扰采用膀胱过度活动症问卷评估,急迫性尿失禁发作次数采用排尿日记确定。
- 采用线性模型检验基线与6个月时平均生物标志物水平及急迫性尿失禁发作次数和症状困扰变化的差异。
主要发现
- 基线时病例与对照的生物标志物水平差异很小, except 原弹性蛋白(p=0.001)和I型胶原N端端肽(p<0.001)。
- 治疗6个月后,两种治疗组胶原酶均下降(p<0.001)。
- 治疗6个月后,A型肉毒毒素组白细胞介素-8升高(p=0.002)和基质金属蛋白酶-9升高(p<0.001)。
- 基线降钙素基因相关肽较高与两种治疗后膀胱过度活动症症状困扰改善较少相关(p=0.007)。
- 基线神经生长因子较高与A型肉毒毒素组膀胱过度活动症症状困扰改善较少相关(p=0.007)。
关键数值与推荐
- p≤0.01表示存在潜在关联的适度证据,p≤0.004表示与结局存在关联的中等证据。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We measured urinary biomarker levels in women with refractory urgency urinary incontinence and controls at baseline and 6 months after treatment with sacral neuromodulation or intradetrusor injection of onabotulinumtoxinA. We also assessed the association of baseline biomarkers with posttreatment urgency urinary incontinence episodes and overactive bladder symptom bother outcomes. MATERIALS AND METHODS: First morning urine samples were collected from consented trial participants and age matched women without urgency urinary incontinence. Biomarkers reflecting general inflammation, neuroinflammation, afferent neurotransmitters and tissue remodeling were measured using standardized enzyme-linked immunosorbent assay and activity assays as appropriate. Symptom bother was assessed by the overactive bladder questionnaire and urgency urinary incontinence episodes were determined by bladder diary. Linear models were used to examine differences in mean biomarker levels and the change in urgency urinary incontinence episodes and symptom bother between baseline and 6 months. Modest evidence of a potential association was represented by p ≤0.01 and p ≤0.004 represented moderate evidence of an association with outcomes. RESULTS: Baseline biomarker levels differed little between cases and controls except tropoelastin (p = 0.001) and N-terminal telopeptide collagen type 1 (p <0.001). Changes in biomarker levels 6 months after intervention included decreases in collagenase (p <0.001) in both treatment groups and increases in interleukin-8 (p = 0.002) and matrix metalloprotease-9 (p <0.001) in the onabotulinumtoxinA group. Higher baseline calcitonin gene-related peptide across both treatments (p = 0.007) and nerve growth factor in the onabotulinumtoxinA arm (p = 0.007) were associated with less reduction in overactive bladder symptom bother. CONCLUSIONS: Refractory urgency urinary incontinence is a complex condition. These data suggest that matrix remodeling and neuropeptide mediation may be involved in its pathophysiological mechanisms and response to treatment.
引用
- Richter HE, Moalli P, Amundsen CL, et al. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls. J Urol. 2017. PMID: 28089729. doi:10.1016/j.juro.2017.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。